Incyte Corporation (INCY)

51,65 -0,27 (-0,52%) Al cierre: 04:00PM EDT

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700
https://www.incyte.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 2524

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Herve Hoppenot	CEO & Chairman	2,89M	N/A	1960
Ms. Christiana Stamoulis MBA	Executive VP & CFO	1,16M	N/A	1971
Dr. Barry P. Flannelly M.B.A., Pharm.D.	Executive VP & GM of North America	996,28k	545,65k	1958
Dr. Steven H. Stein M.D.	Executive VP & Chief Medical Officer	1,22M	N/A	1967
Dr. Pablo J. Cagnoni M.D., Ph.D.	President and Head of Research & Development	N/A	N/A	1963
Mr. Thomas Tray	VP of Finance, Chief Accounting Officer & Controller	N/A	N/A	1978
Mr. Michael James Morrissey	Executive VP & Head of Global Technical Operations	N/A	N/A	1964
Sheila A. Denton	Executive VP, General Counsel & Corporate Secretary	N/A	N/A	1966
Ms. Pamela M. Murphy	Vice President of Investor Relations & Corporate Communications	N/A	N/A	1951
Ms. Paula J. Swain	Executive Vice President of Human Resources	611,92k	4,21M	1958

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Gobierno corporativo

El ISS Governance QualityScore de Incyte Corporation, a día 1 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 3; Tablero: 6; Derechos de los accionistas: 6; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.